MorningLyte -> A Phase III randomized, open-label, international, multicenter study evaluating the efficacy and safety of mosunetuzumab plus lenalidomide in comparison to anti-CD20 mAb plus chemotherapy in subjects with previously untreated high-tumor burden follicular lymphoma

Kategorie: Indolente Lymphome/MCL

EU Clinical Trials Register

Leiter: Herr Prof. Dr. med. Christian Buske

 

Herr Prof. Dr. med. Christian Buske

Universitätsklinikum Ulm

Send e-mail

Informationen zur Studie

Beschreibung

A Phase III randomized, open-label, international, multicenter study evaluating the efficacy and safety of mosunetuzumab plus lenalidomide in comparison to anti-CD20 mAb plus chemotherapy in subjects with previously untreated high-tumor burden follicular lymphoma

Additional documents

• 20230728_Synopsis_MO44842_MorningLyte_Version 0.2_for GLA_edCB.pdf
   

Beteiligte Arbeitsgruppen

Indolente Lymphome